Samil Pharmaceutical Co.,Ltd (KRX:000520)
South Korea · Delayed Price · Currency is KRW 7,400.00
+310.00 (4.37%)
Last updated: Jun 4, 2026, 2:24 PM KST
KRX:000520 Revenue
Samil Pharmaceutical Co.,Ltd had revenue of 52.55B KRW in the quarter ending March 31, 2026, with 0.50% growth. This brings the company's revenue in the last twelve months to 210.51B, down -3.30% year-over-year. In the year 2025, Samil Pharmaceutical Co.,Ltd had annual revenue of 210.25B, down -4.30%.
Revenue (ttm)
210.51B
Revenue Growth
-3.30%
P/S Ratio
0.72
Revenue / Employee
361.09M
Employees
583
Market Cap
150.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 210.25B | -9.45B | -4.30% |
| Dec 31, 2024 | 219.70B | 23.35B | 11.89% |
| Dec 31, 2023 | 196.35B | 16.67B | 9.28% |
| Dec 31, 2022 | 179.68B | 45.43B | 33.84% |
| Dec 31, 2021 | 134.25B | 11.25B | 9.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharmaceutical Co.,Ltd | 534.52B |
| Dongwha Pharm.Co.,Ltd | 501.33B |
| Ilyang Pharmaceutical Co.,Ltd | 275.51B |
| Kyongbo Pharmaceutical | 269.64B |
| HLB Pharmaceutical | 236.59B |
| Daihan Pharmaceutical | 211.44B |
| Hana Pharm | 139.33B |
| CMG Pharmaceutical | 110.12B |